Hiroto Hatakeyama

List of Publications by Citations

53 papers	3,354 citations	33 h-index	57 g-index
61 ext. papers	3,731 ext. citations	8.9 avg, IF	5.24 L-index

#	Paper	IF	Citations
53	A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. *Advanced Drug Delivery Reviews*, **2011**, 63, 152-60	18.5	506
52	The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. *Biological and Pharmaceutical Bulletin*, **2013**, 36, 892-9	2.3	301
51	A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. *Journal of Controlled Release*, **2009**, 139, 127-32	11.7	209
50	Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. *Biomaterials*, **2011**, 32, 4306-16	15.6	168
49	Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. *Journal of Controlled Release*, **2011**, 153, 141-8	11.7	162
48	Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. *International Journal of Pharmaceutics*, **2004**, 281, 25-33	6.5	140
47	Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. *Archives of Pharmacal Research*, **2014**, 37, 4-15	6.1	126
46	Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. *Molecular Therapy*, **2013**, 21, 1195-203	11.7	97
45	Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. *Biomaterials*, **2011**, 32, 5733-42	15.6	93
44	RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. *Journal of Controlled Release*, **2014**, 173, 110-8	11.7	87
43	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. *Nature Communications*, **2016**, 7, 11169	17.4	83
42	2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. *Nature Communications*, **2014**, 5, 3459	17.4	81
41	Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. *Journal of Controlled Release*, **2012**, 162, 225-32	11.7	80
40	The effect of liposomal size on the targeted delivery of doxorubicin to Integrin □3-expressing tumor endothelial cells. *Biomaterials*, **2013**, 34, 5617-27	15.6	77
39	A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. *Journal of Controlled Release*, **2016**, 225, 183-91	11.7	73
38	Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. *ACS Nano*, **2013**, 7, 7534-41	16.7	65
37	The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. *Journal of Controlled Release*, **2014**, 173, 43-50	11.7	56

36	An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. *Biomaterials*, **2014**, 35, 7110-20	15.6	50
35	A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA. *Advanced Healthcare Materials*, **2013**, 2, 1120-5	10.1	50
34	Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. *International Journal of Pharmaceutics*, **2010**, 396, 143-8	6.5	50
33	A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. *Journal of Controlled Release*, **2015**, 200, 97-105	11.7	45
32	Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. *Journal of Hepatology*, **2016**, 64, 547-55	13.4	45
31	Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. *Molecular Therapy*, **2016**, 24, 788-95	11.7	44
30	In vitro optimization of 2∀OMe-4∀thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. *Nucleic Acids Research*, **2013**, 41, 10659-67	20.1	43
29	In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. *Scientific Reports*, **2014**, 4, 4750	4.9	40
28	Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. *Biological and Pharmaceutical Bulletin*, **2009**, 32, 928-32	2.3	39
27	Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. *International Journal of Pharmaceutics*, **2016**, 509, 178-187	6.5	38
26	Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. *Bioconjugate Chemistry*, **2011**, 22, 2082-92	6.3	37
25	Intracellular stability of 2∀OMe-4∀thioribonucleoside modified siRNA leads to long-term RNAi effect. *Nucleic Acids Research*, **2012**, 40, 5787-93	20.1	37
24	Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. *Molecular Therapy - Nucleic Acids*, **2014**, 3, e154	10.7	35
23	Advances in an active and passive targeting to tumor and adipose tissues. *Expert Opinion on Drug Delivery*, **2015**, 12, 41-52	8	34
22	Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. *Molecular Pharmaceutics*, **2014**, 11, 2713-9	5.6	34
21	An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. *International Journal of Pharmaceutics*, **2014**, 465, 77-82	6.5	33
20	Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery. *ACS Biomaterials Science and Engineering*, **2015**, 1, 834-844	5.5	32
19	Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. *Biological and Pharmaceutical Bulletin*, **2014**, 37, 1926-35	2.3	32

18	Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 966-976	6.1	31
17	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 2894-2904	6.1	30
16	Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. *International Journal of Pharmaceutics*, **2015**, 495, 171-178	6.5	21
15	A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. *Molecular Therapy*, **2011**, 19, 1487-98	11.7	20
14	Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. *International Journal of Nanomedicine*, **2014**, 9, 4267-76	7.3	18
13	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. *Cell Reports*, **2016**, 17, 1621-1631	10.1	17
12	A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. *International Journal of Pharmaceutics*, **2011**, 412, 106-14	6.5	14
11	Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System. *Bioconjugate Chemistry*, **2015**, 26, 1266-76	6.3	12
10	Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World. *Journal of Clinical Medicine*, **2020**, 9,	5.1	9
9	Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models **2020**, 8,		9
8	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. *Methods in Molecular Biology*, **2016**, 1402, 189-197	1.4	8
7	Delivery of Nucleic Acids and Gene Delivery **2011**, 411-444		6
6	Ornithine and tryptophan analogs as efficient polycations for short interference RNA delivery to tumor cells. *Biological and Pharmaceutical Bulletin*, **2010**, 33, 1246-9	2.3	6
5	Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors. *Cancers*, **2020**, 12,	6.6	5
4	A novel nonviral gene delivery system: multifunctional envelope-type nano device. *Advances in Biochemical Engineering/Biotechnology*, **2010**, 119, 197-230	1.7	4
3	Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2771-2779	3.9	3
2	siRNA delivery by multifunctional envelope-type nano device (MEND). *Drug Delivery System*, **2010**, 25, 590-597	0	1
1	PEG dilemma- nucleic acids delivery to cancers by controlling biodistribution and intracellular trafficking. *Drug Delivery System*, **2016**, 31, 293-299	0	0